Clinical and microbiological end points in the treatment of pneumonia.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 18986291.
- Also identified by DOI 10.1086/591406.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
The US Food and Drug Administration is reviewing its criteria for evaluating new antibiotics for the treatment of bacterial pneumonia. Although there are descriptions of hundreds of comparative studies of various antimicrobials, there is surprisingly little scientific literature on how the evaluations should be done. This brief contribution outlines areas for further consideration as new drugs are evaluated.
Medical subject headings
- Anti-Bacterial Agents
- Clinical Trials as Topic
- Community-Acquired Infections
- Pneumonia, Bacterial